Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Leukemia. 2022 Nov 5;37(1):154–163. doi: 10.1038/s41375-022-01739-2

Figure 3. Outcomes among patients receiving first treatment after CD19-CAR-T.

Figure 3.

(A) Post-treatment-overall survival (OS) and post-treatment-event-free survival (EFS) from initiation of first-line treatment post-CD19-CAR-T. (B) Treatment components among the most common treatments groups. Treatment strategies of the remaining treatment groups are listed in Table S3. (C) First-line treatment strategies, by disease stage at time of relapse or progression, after CD19-CAR-T treatment failure. (D) Response rates by treatment group. (E) Post-treatment-OS by leading treatment strategies. (F) Overall survival by prognostic strata.

AutoSCT – autologous stem cell transplantation; GCB – germinal center B-cell; CRS – cytokine release storm; ICANS – immune effector cell-associated neurotoxicity syndrome; LDH – lactate dehydrogenase; ICI – immune checkpoint inhibitor; BTKi – Bruton’s tyrosine kinase inhibitor; ISRT – involved site radiation therapy; alloHCT – allogeneic hematopoietic stem cell transplantation; Ibr - Ibrutinib; Tafa – tafasitimab; Benda - bendamustine; CR – complete response; PR – partial response; SD/PD – stable disease/progressive disease